AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11495669 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 18
Study 11495669 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 18
Study 9766795 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet von Willebrand factor (vWF) activity levels in HPS patients
Number of subjects: 30
Study 9766795 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma von Willebrand factor (vWF) activity levels in HPS patients
Number of subjects: 30
Study 9766795 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimeric structure of plasma vWF in 11 HPS patients
Number of subjects: 30
Study 9766795 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of platelet and plasma vWF values with bleeding histories
Number of subjects: 30
Study 8153984 — intervention group
Group type: COMPARATOR
Intervention: IVER 100 (100 micrograms/kg)
Number of subjects: 43
Study 8153984 — intervention group
Group type: EXPERIMENTAL
Intervention: IVER 400 (400 micrograms/kg)
Number of subjects: 43
Study 2111327 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 235
Study 2111327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 7212246 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 0
Study 7212246 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 0
Study 7212246 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 0
Study 7212246 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 0
Study 7212246 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 0
Study 31318748 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (n = 32)
Number of subjects: 65
Study 31318748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (n = 33)
Number of subjects: 65
Study 28061321 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous vitamin E ointment application (Group 1)
Number of subjects: 101
Study 28061321 — intervention group
Group type: COMPARATOR
Intervention: No vitamin E ointment application (Group 2)
Number of subjects: 101
Study 26001670 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cognitive behavioral therapy for PGD (PG-CBT)
Number of subjects: 51
Study 26001670 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait list)
Number of subjects: 51
Study 24303144 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 12
Study 24303144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21129746 — intervention group
Group type: COMPARATOR
Intervention: Non-users of lipid-lowering treatment (LLT)
Number of subjects: 1280
Study 21129746 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 1280
Study 21129746 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrate users
Number of subjects: 1280
Study 19413147 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline polysomnograms from all children
Number of subjects: 36
Study 19413147 — intervention group
Group type: EXPERIMENTAL
Intervention: Night 1 PLMS index
Number of subjects: 36
Study 19413147 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual data for 15 children with 5 or more PLMS per hour
Number of subjects: 36
Study 19413147 — intervention group
Group type: EXPERIMENTAL
Intervention: PLMS indexes of children who were medication free for a third and fourth night (n = 7) or just a third night (n = 2)
Number of subjects: 36
Study 17388751 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus (DK)
Number of subjects: 60
Study 17388751 — intervention group
Group type: COMPARATOR
Intervention: Handihaler (HH)
Number of subjects: 60
Study 17388751 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation technique
Number of subjects: 60
Study 17388751 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation resistance
Number of subjects: 60
Study 15220017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.28 mg/kg IV)
Number of subjects: 25
Study 15220017 — intervention group
Group type: COMPARATOR
Intervention: Diazepam vehicle (alcohol and propylene glycol IV)
Number of subjects: 25
Study 15220017 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 25
Study 11231977 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen, 0.625 mg/day
Number of subjects: 25
Study 9748117 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU dose adjusted according to the 5FU area under the curve (AUC0‐48h; PK‐arm)
Number of subjects: 122
Study 9748117 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of 5FU (St‐arm; 4 g/m2)
Number of subjects: 122
Study 8040918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Skills Training Program (ASTP), a cognitive behavioral approach, details of dosage and duration not specified.
Number of subjects: 0
Study 8040918 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 3555598 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0
Study 3555598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31896568 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-caliber coils
Number of subjects: 210
Study 31896568 — intervention group
Group type: COMPARATOR
Intervention: 10-caliber coils (Control)
Number of subjects: 210
Study 30243201 — intervention group
Group type: EXPERIMENTAL
Intervention: EM-guided nasoenteral feeding tube placement
Number of subjects: 161
Study 30243201 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic nasoenteral feeding tube placement
Number of subjects: 161
Study 28318867 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 60
Study 28318867 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 60
Study 28318867 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 26205998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral zoned insoles (2, 4, and 6mm)
Number of subjects: 15
Study 26205998 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial zoned insoles (2, 4, and 6mm)
Number of subjects: 15
Study 26205998 — intervention group
Group type: COMPARATOR
Intervention: Control insoles (0mm)
Number of subjects: 15
Study 26205998 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired vision condition
Number of subjects: 15
Study 23266280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary planning intervention (leaflet on fruit consumption with a planning sheet)
Number of subjects: 165
Study 23266280 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 165
Study 21378250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 400
Study 21378250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study 18180620 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg) + Propranolol (80 mg)
Number of subjects: 54
Study 18180620 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 54
Study 18180620 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 54
Study 18180620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16609087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (various regimens including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel) for ER-negative tumors
Number of subjects: 6644
Study 16609087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (various regimens including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel) for ER-positive tumors
Number of subjects: 6644
Study 16609087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for ER-negative tumors
Number of subjects: 6644
Study 16609087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for ER-positive tumors
Number of subjects: 6644
Study 12969165 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 26
Study 12969165 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 26
Study 10780142 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy child (HL)
Number of subjects: 0
Study 10780142 — intervention group
Group type: COMPARATOR
Intervention: Child in remission from cancer and no longer undergoing treatment (RCL)
Number of subjects: 0
Study 10780142 — intervention group
Group type: COMPARATOR
Intervention: Child in remission and still undergoing treatment (RCTL)
Number of subjects: 0
Study 8627642 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide‐methotrexate‐fluorouracil‐vincristine‐prednisone) for two 6‐week cycles or six 4‐week cycles, followed by VATH (vinblastine‐doxorubicin‐thiotepa‐fluoxymesterone)
Number of subjects: 280
Study 1471706 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol treatment for 6 weeks
Number of subjects: 49
Study 1471706 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study 6718766 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotensin infusion at 3 pmol X kg‐1 X min‐1 for 4 h
Number of subjects: 6
Study 6718766 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotensin infusion
Number of subjects: 6
Study 30583082 — intervention group
Group type: EXPERIMENTAL
Intervention: 12,000 IU vitamin D3
Number of subjects: 379
Study 30583082 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,000 IU vitamin D3
Number of subjects: 379
Study 30583082 — intervention group
Group type: EXPERIMENTAL
Intervention: 48,000 IU vitamin D3
Number of subjects: 379
Study 30583082 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 379
Study 30106621 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast before exercise (BE)
Number of subjects: 12
Study 30106621 — intervention group
Group type: COMPARATOR
Intervention: Overnight fasted exercise (FE)
Number of subjects: 12
Study 26919080 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensibilize Nano‐P paste (20% hydroxyapatite, potassium nitrate, and sodium fluoride; 9000 ppm fluoride)
Number of subjects: 28
Study 26919080 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensibilize Nano‐P associated with experimental home‐care pastes (10% HA, potassium nitrate, and sodium fluoride; 900 ppm fluoride)
Number of subjects: 28
Study 26919080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Relief professional paste (8% arginine with Pro‐Argin technology) associated with home‐care toothpaste (8% arginine, sodium monofluorophosphate, 1450 ppm fluoride)
Number of subjects: 28
Study 26919080 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat professional varnish (NaF varnish, 22,600 ppm fluoride)
Number of subjects: 28
Study 24041748 — intervention group
Group type: EXPERIMENTAL
Intervention: DrAFT‐CS
Number of subjects: 176
Study 24041748 — intervention group
Group type: EXPERIMENTAL
Intervention: DrAFT‐CS+
Number of subjects: 176
Study 24041748 — intervention group
Group type: COMPARATOR
Intervention: Moderation skills only (MSO)
Number of subjects: 176
Study 24041748 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 176
Study 23096033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (2 tablets twice a day) and standard therapy (acetylsalicylic acid and antihypertensive drugs)
Number of subjects: 60
Study 23096033 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (acetylsalicylic acid and antihypertensive drugs)
Number of subjects: 60
Study 20666654 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 32
Study 20666654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E (VCE)
Number of subjects: 32
Study 20666654 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus Vitamins C and E (EX + VCE)
Number of subjects: 32
Study 17623754 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg daily)
Number of subjects: 62
Study 17623754 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide (400 microg per day in two doses)
Number of subjects: 62
Study 12124481 — intervention group
Group type: COMPARATOR
Intervention: AGAb bone marrow immunoscintigraphy (370 MBq of (99m)Tc labelled anti‐NCA‐95 antigranulocyte antibodies)
Number of subjects: 23
Study 12124481 — intervention group
Group type: COMPARATOR
Intervention: AGAb bone marrow immunoscintigraphy
Number of subjects: 23
Study 10214632 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured filters (Blue tints, Diagnosed tints)
Number of subjects: 148
Study 10214632 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo tints
Number of subjects: 148
Study 10214632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coloured filters)
Number of subjects: 148
Study 7825764 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline recommendations for discharge by day 3
Number of subjects: 230
Study 7825764 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent review classification
Number of subjects: 230
Study 7825764 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct classification of patients
Number of subjects: 230
Study 7825764 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of illness measurement
Number of subjects: 230
Study 7825764 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician compliance with guidelines
Number of subjects: 230
Study 2114131 — intervention group
Group type: EXPERIMENTAL
Intervention: High referral general practitioners (n = 192)
Number of subjects: 280
Study 2114131 — intervention group
Group type: COMPARATOR
Intervention: Average referral general practitioners (n = 88)
Number of subjects: 280
Study 385399 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 30‐60 mg daily
Number of subjects: 40
Study 385399 — intervention group
Group type: COMPARATOR
Intervention: diazepam 15‐30 mg daily
Number of subjects: 40
Study 385399 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 30707761 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 232
Study 30707761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 28383292 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve electrical stimulation (PNS)
Number of subjects: 32
Study 28383292 — intervention group
Group type: COMPARATOR
Intervention: Placebo PNS
Number of subjects: 32
Study 25840004 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group received an intranasal dose of 'serotonin' (placebo) prior to the second stress test.
Number of subjects: 0
Study 25840004 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study 23827259 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (192 mg)
Number of subjects: 57
Study 23827259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naltrexone (384 mg)
Number of subjects: 57
Study 23827259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 21470361 — intervention group
Group type: EXPERIMENTAL
Intervention: Single (30-min exercise)
Number of subjects: 9
Study 21470361 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated (three 10-min bouts of exercise)
Number of subjects: 9
Study 21470361 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 9
Study 19788970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 302
Study 17692720 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 618
Study 17692720 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 0.25 mg BID
Number of subjects: 618
Study 17692720 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 0.5 mg BID
Number of subjects: 618
Study 17692720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 17692720 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (all doses)
Number of subjects: 618
Study 15122610 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative resection (R0)
Number of subjects: 366
Study 15122610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph-node negative status
Number of subjects: 366
Study 15122610 — intervention group
Group type: COMPARATOR
Intervention: Surgical exploration
Number of subjects: 366
Study 11281235 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-blocking drugs
Number of subjects: 74
Study 11281235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 74
Study 11281235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 74
Study 11281235 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 74
Study 11281235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11281235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential monotherapy
Number of subjects: 74
Study 11281235 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 74
Study 11281235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors, calcium-blocking drugs, diuretics
Number of subjects: 74
Study 9579506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 453
Study 9579506 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 453
Study 7914958 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 2649
Study 7914958 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 2649
Study 2645924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-restricted diet
Number of subjects: 0
Study 4907514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, 1 g. four times a day for 28 days
Number of subjects: 68
Study 4907514 — intervention group
Group type: COMPARATOR
Intervention: Placebo in identical capsules for 28 days
Number of subjects: 68
Study 31179008 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 600 mg
Number of subjects: 750
Study 31179008 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 200 mg
Number of subjects: 750
Study 31179008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 28578139 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes patients without peripheral neuropathy (DM)
Number of subjects: 67
Study 28578139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate/severe diabetic peripheral neuropathy (DPN)
Number of subjects: 67
Study 28578139 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls (Ctrl)
Number of subjects: 67
Study 26009529 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician training on predominantly non-verbal communication
Number of subjects: 16
Study 26009529 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 16
Study 23725973 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine-containing peritoneal dialysis solution (0.1%, 2 g/bag)
Number of subjects: 35
Study 23725973 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose-based solution (1.5% or 2.5%)
Number of subjects: 35
Study 23725973 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine-containing solution
Number of subjects: 35
Study 23725973 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose-based solution
Number of subjects: 35
Study 21740832 — intervention group
Group type: EXPERIMENTAL
Intervention: SEM‐rTMS
Number of subjects: 164
Study 21740832 — intervention group
Group type: COMPARATOR
Intervention: C‐rTMS
Number of subjects: 164
Study 21740832 — intervention group
Group type: COMPARATOR
Intervention: sham‐rTMS
Number of subjects: 164
Study 19719939 — intervention group
Group type: EXPERIMENTAL
Intervention: BHR group (metal-on-metal femoral heads, average size 45 mm)
Number of subjects: 31
Study 19719939 — intervention group
Group type: EXPERIMENTAL
Intervention: BHR group
Number of subjects: 31
Study 19719939 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (28-mm metal-on-polyethylene heads)
Number of subjects: 31
Study 17615905 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus multivitamin syrup
Number of subjects: 154
Study 17615905 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin syrup
Number of subjects: 154
Study 12926799 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (25 mg) twice daily for 36 months
Number of subjects: 62
Study 12926799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saccharose capsules)
Number of subjects: 62
Study 10868832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg
Number of subjects: 289
Study 10868832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 289
Study 10868832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 180 mg
Number of subjects: 289
Study 10868832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 9213836 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 26
Study 9213836 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 26
Study 8444727 — intervention group
Group type: EXPERIMENTAL
Intervention: High total work-exercise protocol [1 min rest, 10 RM load (H10/1)]
Number of subjects: 8
Study 8444727 — intervention group
Group type: EXPERIMENTAL
Intervention: All heavy-resistance exercise protocols
Number of subjects: 8
Study 8444727 — intervention group
Group type: EXPERIMENTAL
Intervention: H10/1 protocol
Number of subjects: 8
Study 3536640 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 4
Study 3536640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 29049845 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group (IG) performing endurance, strength, and flexibility training three times per week
Number of subjects: 53
Study 29049845 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with a nonexercise program
Number of subjects: 53